Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) EBT Margin (2024)

Zentalis Pharmaceuticals has reported EBT Margin over the past 1 years, most recently at 177.47% for Q4 2024.

  • For Q4 2024, EBT Margin changed N/A year-over-year to 177.47%; the TTM value through Sep 2025 reached 556.56%, down 11503.0%, while the annual FY2024 figure was 245.74%, N/A changed from the prior year.
  • EBT Margin for Q4 2024 was 177.47% at Zentalis Pharmaceuticals, down from 25.11% in the prior quarter.
  • Over five years, EBT Margin peaked at 25.11% in Q1 2024 and troughed at 177.47% in Q4 2024.